Chen H, et al. - Experts compared the effectiveness and potential mechanisms of budesonide nasal spray (BD), oral montelukast (MNT), and combination therapy comprising a half-dose of budesonide plus montelukast (hBD+MNT) in seasonal allergic rhinitis (SAR) patients. Findings suggested an overall better efficacy profile of the hBD+MNT combination than BD and MNT monotherapy for treatment of SAR. In nasal mucosa, T-helper 1 (Th1) and Th2 cells decreased and T-regulatory (Treg) cells increased with BD and with MNT, Th1 cells decreased and Treg cells increased in the peripheral blood, and this trend was reflected with hBD+MNT.